Trial Profile
A double-blind, randomized, 4-period crossover study to evaluate the effect of ASP5633 on the opening urethral pressure (OUP) in healthy females
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs ASP 5633 (Primary)
- Indications Urinary incontinence
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 24 Oct 2016 New trial record
- 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society